Recombinant Human Melanoma Antigen Recognized By T-Cells 1 (MLANA) Protein (His)

Name: Recombinant Human Melanoma Antigen Recognized By T-Cells 1 (MLANA) Protein (His)
Brand: Beta LifeScience
SKU: BLC-04193P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Melanoma Antigen Recognized By T-Cells 1 (MLANA) Protein (His) is produced by our Yeast expression system. This is a full length protein.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	Q16655
Target Symbol	MLANA
Synonyms	Antigen LB39 AA; Antigen LB39-AA; Antigen SK29 AA; Antigen SK29-AA; MAR1_HUMAN; MART 1; MART-1; MART1; Melan A; Melan A protein; Melanoma antigen recognized by T cells 1; Melanoma antigen recognized by T-cells 1; MLAN A; MLANA; OTTHUMP00000021036; OTTHUMP00000021037; OTTHUMP00000021038; Protein Melan-A
Species	Homo sapiens (Human)
Expression System	Yeast
Tag	N-6His
Target Protein Sequence	MPREDAHFIYGYPKKGHGHSYTTAEEAAGIGILTVILGVLLLIGCWYCRRRNGYRALMDKSLHVGTQCALTRRCPQEGFDHRDSKVSLQEKNCEPVVPNAPPAYEKLSAEQSPPPYSP
Expression Range	1-118aa
Protein Length	Full Length
Mol. Weight	15.2kDa
Research Area	Cancer
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Involved in melanosome biogenesis by ensuring the stability of GPR143. Plays a vital role in the expression, stability, trafficking, and processing of melanocyte protein PMEL, which is critical to the formation of stage II melanosomes.
Subcellular Location	Endoplasmic reticulum membrane; Single-pass type III membrane protein. Golgi apparatus. Golgi apparatus, trans-Golgi network membrane. Melanosome. Note=Also found in small vesicles and tubules dispersed over the entire cytoplasm. A small fraction of the protein is inserted into the membrane in an inverted orientation. Inversion of membrane topology results in the relocalization of the protein from a predominant Golgi/post-Golgi area to the endoplasmic reticulum. Melanoma cells expressing the protein with an inverted membrane topology are more effectively recognized by specific cytolytic T-lymphocytes than those expressing the protein in its native membrane orientation.
Database References	HGNC: 7124 OMIM: 605513 KEGG: hsa:2315 STRING: 9606.ENSP00000370880 UniGene: PMID: 27533878 Report automated quantification of proliferation with automated hot-spot selection in phosphohistone H3/MART1 dual-stained stage I/II melanoma. PMID: 27062658 Suggest MelanA-negative spindle-cell associated melanoma constitutes a distinct inflammatory phenotype correlated with dense infiltration of CD163 macrophages and loss of E-cadherin. PMID: 25602697 Inhibin alpha-subunit, Melan A and MNF116 were not sensitive for pheochromocytomas. PMID: 25329118 the presence of antibody and T-cell immune responses directed against the melanocyte-differentiation-antigens MART-1 (Melan-A), tyrosinase and gp100 in patients with melanoma-associated leucoderma, as compared to patients with vitiligo. PMID: 25043574 Knockdown of T-bet expression in Mart-127-35 -specific T-cell-receptor-engineered human CD4(+) CD25(-) and CD8(+) T cells attenuates effector function. PMID: 25495780 Melan-A was useful to confirm the diagnosis of lentigo maligna in early lesions and to differentiate these from chronically sun-damaged skin. PMID: 24394300 Misinitiation of intrathymic MART-1 transcription and biased TCR usage explain the high frequency of MART-1-specific T cells. PMID: 24846220 Comprehensive characterization of the marginal and joint distributions for S100, HMB-45, and Melan-A across a large series of cutaneous melanomas revealed diversity of expression across this group of antigens. PMID: 23899062 melan A (A103) is not expressed in mesotheliomas PMID: 22820661 Report diagnostic role of immunohistochemical staining for Melan-A in evaluating primary melanoma and, specifically, in situ melanoma cases. PMID: 22688397 In this study, production of the C terminus of the Melan-A(26-35) epitope requires cleavage within a hydrophobic stretch, after V35. Hence, the standard proteasome is the only proteasome able to produce the C terminus of this epitope. PMID: 22925930 naturally occurring MART-1 melanoma antigen can be taken-up from dying melanoma cells into DC or MAK and both cell types can induce specific CD8(+) T cell cross-presentation thereafter. PMID: 22768350 The presence of circulating T cells responding to Melan-A or NY-ESO-1 had strong independent prognostic impact on survival in advanced melanoma. PMID: 22529253 The modified melan-A long peptides (not their wild-type counterparts) give rise to highly sustained cross-presentation capacity by monocyte-derived dendritic cells and could be used as tumor vaccines for treatment of melanoma patients. PMID: 22291187 Aberrant expression of Melan-A and MART-1 in AFX and undifferentiated pleomorphic sarcoma of the skin represents an important diagnostic pitfall with potential for misdiagnosis as melanoma. PMID: 22050092 MART-1- and gp100-expressing and -non-expressing melanoma cells are equally proliferative in tumors and clonogenic in vitro. PMID: 21993558 we established several CD4 T-cell clones that recognized a peptide that is embedded within Melan-A/MART-121-50, in a HLA-DPB1*0501 restricted manner PMID: 21760531 Melanocyte MART-1 may correlate to the autoimmune mechanism in children with vitiligo. PMID: 19861278 The differential expression of Mart-1 was investigated in four human uveal melanoma cells. PMID: 21667026 Translocation of the BCL2 gene on the chromosome band 18q21.3 and MYC translocation to 14q32/IGH or less commonly to 2p11/IGK in an identical cell is termed BCL2 and MYC dual-hit lymphoma/leukemia PMID: 21362015 Both semiscale and fullscale quantitative analyses of Ki67/MART1 stains are valuable diagnostic tools to distinguish melanomas and nevi with a large degree of certainty. PMID: 21610457 Molecular upstaging of MART-1 using rt-pcr was correlated with prognosis in melanoma patients PMID: 21135695 determined the crystal structure of a phosphopeptide derived from melanoma antigen recognized by T cells-1 (pMART-1), selectively expressed by melanomas, in complex with HLA-DR1 PMID: 20417641 OA1 interacts with MART-1 at early stages of melanogenesis to control melanosome identity and composition. PMID: 19717472 unexpected high frequency of T cells specific for the self-antigen Melan-A/MART-1 in CD8 single-positive thymocytes from human histocompatibility leukocyte antigen-A2 healthy individuals PMID: 11854361 Melanosomes from an Achilles tendon clear-cell sarcoma showed expression of the Melan-A gene. PMID: 12072203 The high frequency of Melan-A multimer(+) T cells can be explained by the existence of largely cross-reactive subsets of naive CD8(+) T cells displaying multiple specificities. PMID: 12119345 dominant function of TCRAV2 segment in forming the TCR repertoire specific for the human self Ag Melan-A/MART-1 PMID: 12444131 Data show that MITF appears to regulate the expression of the SILV and MLANA genes. PMID: 12819038 Antigen-specific T lymphocyte reactivity to MelanA/MART-1 and tyrosinase peptides was not observed ex vivo in our vitiligo patients, and only one patient demonstrated responses to MelanA/MART-1 PMID: 12925214 adrenocortical neoplasms showed strong and diffuse granular cytoplasmic staining for Melan A. No nuclear reaction was observed. PMID: 14663359 the expression of Melan-A/MART-1 in patient-derived cell cultures may help to identify a group of melanoma patients with prolonged survival PMID: 15305155 Melan-A is very useful in distinguishing between desmoplastic melanoma and sclerotic nevi. PMID: 15618925 Data suggest that MART-1 is indispensable for Pmel17 function and thus plays an important role in regulating mammalian pigmentation. PMID: 15695812 Two new Melan-A-derived CD4+ T cell epitopes have been identified that map to the 1-20 and 91-110 regions of the protein and are restricted by HLA-DR11 and HLA-DR52 molecules. PMID: 16814609 Blocking MAPK signaling augments antigen levels, thereby enhancing Melan-A/MART-1-specific cytotoxic T-cell responses to antigen-negative cells following MEK inhibition treatment. PMID: 17050671 Two novel Melan-A/MART-1-derived sequences recognized by CD4 T cells from melanoma patients provide the basis for monitoring of naturally occurring and vaccine-induced Melan-A/MART-1-specific CD4 T cell responses. PMID: 17082590 HMB-45 and Melan-A combined were positive in 100% of the renal angiomyolipomas. PMID: 17227112 Data show that the MAT-1 26-35 and 27-35 peptides adopt strikingly different conformations when bound to HLA-A2. PMID: 17719062 t cell recaptor antigens and the major histocompatibilyt complex are complexed with this protein. PMID: 17768347 the combinational characterization of calretinin (either by polyclonal or monoclonal antibody), inhibin alpha, and Melan-A expression is of great significance in the differential diagnosis of adrenocortical tumors. PMID: 18091323 these data significantly enlarge the fraction of melanoma patients susceptible to benefit from a Melan-A/MART1 vaccine approach. PMID: 18097665 Measurement of Melan-A, gp100, MAGE-3, MIA and tyrosinase represents a prognostic factor and a method for early detection of metastasis and treatment response of melanoma patients. PMID: 18181974 Although melan-A-specific T cells were detectable, they are unlikely to be involved in the etiopathogenesis of vitiligo. PMID: 18337837 Increased staining with Melan-A, in an actinic keratosis, or solar lentigo should raise the possibility of a contiguous melanoma in situ. PMID: 18494818 results show a complex pattern of changes in the expression of Melan-A in melanomas depending on the location of melanoma cells within individual skin layers PMID: 18626310 the generation of larger numbers of ELAGIGILTV ((MART-1 26-35, A27L)-specific CD8+ T cells correlates negatively with the acquisition of a CD45RA+CCR7- phenotype and cytotoxic capacity. PMID: 19050104 T-cell receptor beta chain sequences of Melan-A-specific clonotypes obtained from melanoma patients were highly heterogeneous, but displayed a preferential usage of few TRBV and TRBJ segments. PMID: 19317896 Case Report: Melan-a-positive "pseudomelanocytic nests": a pitfall in the histopathologic and immunohistochemical diagnosis of pigmented lesions on sun-damaged skin. PMID: 19384076

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.